ADXN · NASDAQ
Addex Therapeutics (ADXN) Stock Price & Fundamentals
Addex Therapeutics (ADXN) closed at $423.92 on Oct 9, 2026, down 1.14% from the previous close of $428.79.
Share price, past year
1Y +17.19%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $423.92 |
| Sep 30, 2026 | $424.61 |
| Aug 31, 2026 | $416.36 |
| Jul 31, 2026 | $407.83 |
| Jun 30, 2026 | $442.31 |
| May 29, 2026 | $410.15 |
| Apr 30, 2026 | $386.60 |
| Mar 31, 2026 | $372.16 |
| Feb 27, 2026 | $374.75 |
| Jan 30, 2026 | $362.75 |
| Dec 31, 2025 | $359.31 |
| Nov 28, 2025 | $374.05 |
| Oct 31, 2025 | $379.68 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 147.8M
- Dividend yield
- —
- 52-week range
- $354.79 – $443.42
Market cap, P/E and dividend yield aren't shown for Addex Therapeutics yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in Swiss francs.
Financials
Addex Therapeutics reported revenue of CHF 404.10K for fiscal 2024, down 74.95% from fiscal 2023.
Figures are in Swiss francs (CHF), as Addex Therapeutics reports them to the SEC.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | CHF 404.10K | −75.0% | — | — | CHF 0.07 | −CHF 5.37M |
| FY2023ended Dec 31, 2023 | CHF 1.61M | +13.4% | — | — | −CHF 0.14 | −CHF 8.00M |
| FY2022ended Dec 31, 2022 | CHF 1.42M | −51.2% | — | — | −CHF 0.46 | −CHF 16.44M |
| FY2021ended Dec 31, 2021 | CHF 2.92M | −19.3% | — | — | −CHF 0.45 | −CHF 14.74M |
| FY2020ended Dec 31, 2020 | CHF 3.61M | +30.8% | — | — | −CHF 0.48 | −CHF 12.24M |
| FY2019ended Dec 31, 2019 | CHF 2.76M | −54.3% | — | — | −CHF 0.56 | −CHF 9.51M |
| FY2018ended Dec 31, 2018 | CHF 6.04M | — | — | — | — | CHF 1.74M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2024ended Jun 30, 2024 | CHF 115.28K | — | CHF 0.13 |
| Q2 FY2023ended Jun 30, 2023 | CHF 630.88K | — | −CHF 0.04 |
| Q2 FY2022ended Jun 30, 2022 | CHF 183.35K | — | −CHF 0.19 |
| Q2 FY2021ended Jun 30, 2021 | CHF 992.60K | — | −CHF 0.14 |
Company profile
- Name
- Addex Therapeutics Ltd.
- Ticker
- ADXN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Chemin Des Mines 9, Geneva, V8 CH-1202
- Incorporated in
- V8
- Fiscal year ends
- December
- SEC CIK
- 0001574232
Recent SEC filings
- May 15, 2026
- May 15, 2025
- Apr 18, 2024
- Mar 30, 2023
- Mar 10, 2022
- Mar 11, 2021
- Apr 27, 2020
Frequently asked questions
What is Addex Therapeutics's stock price?
Addex Therapeutics (ADXN) closed at $423.92 on Oct 9, 2026, down 1.14% from the previous close of $428.79.
How much revenue does Addex Therapeutics make?
Addex Therapeutics reported revenue of CHF 404.10K for fiscal 2024, down 74.95% from fiscal 2023.
Sources and methodology
Fundamentals come from Addex Therapeutics Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures